吉非替尼与厄洛替尼二线治疗晚期非小细胞肺癌的对比研究  

Comparison of the efficacy of gefitinib and erlotinib as a second line treatment for advanced non-small cell lung cancer

作　　者：汪海岩[1] 张德芳[1] 

机构地区：[1]徐州医学院附属医院肿瘤内科,221006

出　　处：《实用医学杂志》2012年第20期3444-3446,共3页The Journal of Practical Medicine

摘　　要：目的:比较表皮生长因子受体酪氨酸激酶抑制剂吉非替尼与厄洛替尼治疗一线化疗失败的晚期非小细胞肺癌(NSCLC)的疗效性及安全性。方法:83例一线治疗失败的NSCLC患者,接受厄洛替尼治疗的患者42例,接受吉非替尼治疗的患者41例,两组患者基本情况大致平衡,并评价两组患者的疗效、无进展生存时间(PFS)、中位生存时间(MST)和毒副反应。结果:比较两组患者中位PFS,中位OS等指标,差异均无统计学意义(P>0.05)。厄洛替尼组较吉非替尼组患者药物毒副反应的发生率较高。两组患者肿瘤病理类型比较有统计学意义(P<0.05),厄洛替尼组中肺鳞癌患者的生存期较吉非替尼组明显延长。结论:在标准一线化疗失败的晚期NSCLC患者中,吉非替尼与厄洛替尼的总体疗效相似,对于肺鳞癌患者厄洛替尼能明显延长患者的生存期,但副反应的发生率高于吉非替尼组患者。Objective To compare the efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and erlotinib alone as a second line treatment for patients with advanced non-small cell lung cancer（NSCLC） who were failed in the first-line chemotherapy.Methods Among the 83 patients who were failed in the first-line treatment for NSCLC,41 received gefitinib（gefitinib group） and 42 received erlotinib（erlotinib） therapy.The efficacy,progression-free survival time（PFS）,median survival time（MST）,and toxicity of the two groups were compared.Results The median PFS and median OS were not significantly different between the two groups（P 〉 0.05）.The rate of adverse events in erlotinib group was higher than that in gefitinib group.The histological types of tumor were significantly different between the two groups（P 〈 0.05）,and the survival time in patients with squamous carcinoma in erlotinib group was longer than that in gefitinib group.Conclusion In the advanced NSCLC patients with standard first-line chemotherapy treatment failure,gefitinib and erlotinib had the similar overall efficacy.

关 键 词：癌 非小细胞肺 吉非替尼 厄洛替尼 化疗 

分 类 号：R734.2[医药卫生—肿瘤]